The association of copper (Cu) defi ciency with cardiomyopathy and other forms of cardiac disease has been recognized for a long time (1) , but its clinical signifi cance has not been fully explored. The current US-Canadian Recommended Dietary Allowance (RDA) for Cu is 0.9 mg/day with a tolerable upper intake level of 10 mg/day for adults 19 years of age or older (2) . A debate continues regarding the appropriateness of the RDA for Cu (3) . A human study has examined the potential adverse eff ects of marginal dietary Cu restriction on the cardiovascular system (4) . Among 24 subjects consuming a typical American diet (1.03 mg Cu/day), four subjects suff ered from cardiac complications after consuming the diet for 4-10 wk. In this case, preexisting cardiac conditions cannot be excluded; however, the fact that these abnormalities appeared after the subjects were fed the controlled low Cu diet does suggest a detrimental eff ect of low levels of Cu. Moreover, these cardiac defects disappeared after the aff ected subjects were supplemented with 3.0 mg Cu/day (4) .
An early study of hearts from people who died from ischemic heart disease showed that Cu concentrations were decreased in the un injured tissues of the infarcted hearts relative to normal heart tissues (5) . Another study showed that Cu concentrations decreased in the hearts of people who died from acute ischemic infarction (6) . The death rate from ischemic heart dis ease in soft water areas was found to be increased, and Cu concentrations were lower in the hearts of people who died from chronic ischemic heart disease (7, 8) .
Cu supplementation can reverse hypertrophic cardiomyopathy in some patients. One example of this is a rare congenital condition of Sco2 mutations, which aff ects Cu metabolism and predisposes to hypertrophic cardiomyopathy. Sco2 is an important Cu chaperon for cytochrome c oxidase (CCO), and mutations in Sco2 result in suppressed CCO activity (9) . Patients with mutations in Sco2 developed severe hyper trophic cardiomyopathy (9) . A SCO2 patient with severe hypertrophic cardiomyopathy was treated with Cu-histidine. This Cu supplement therapy caused reversal of the hypertrophic cardiomyopathy along with signifi cant improvement in all parameters of heart function and normalization of ECG signs and blood pressure (10) . A recent study in a small population of chronic heart failure patients has shown that dietary supplementation with micronutrients for 9 mo increases left ventricle ejection and decreases left ventricle volume along with improvement of quality of life (11) . Among the formulated micronutrients in this study was Cu (1.2 mg/day).
To provide a scientifi c basis for Cu supplementationinduced regression of hypertrophic cardiomyopathy, we used a mouse model of cardiac hypertrophy and dysfunction produced by ascending aortic constriction. In the present study, we found that dietary supplementation with physiologically relevant levels of Cu reverses cardiac hypertrophy and dysfunction even in the presence of chronic pressure overload. The cardiac eff ect of dietary Cu supplementation is associated with restoration of normal vascular epithelial growth factor (VEGF) expression and enhanced angiogenesis. In the presence of anti-VEGF antibody, dietary Cu supplementation failed to reverse the preestablished heart hypertrophy and dysfunction. We further found that Cu is required for hypoxia-inducible factor (HIF)-1α transcription activity, which requires the Cu chaperon for superoxide dismutase-1 (CCS) for activation of VEGF expression. These results suggest that dietary Cu supplementation can improve the condition of hypertrophic cardiomyopathy through, at least in part, CCS-mediated activation of HIF-1α transcription factor for VEGF gene expression.
RESULTS

Regression of cardiac hypertrophy and dysfunction by Cu supplementation
We subjected adult (10-12 wk old) male C57BL/6J mice to chronic pressure overload generated by ascending aortic constriction (AAC) along with sham surgery controls. In mice fed a diet containing RDA adequate levels of Cu (6 mg Cu/kg), cardiac hypertrophy was observed as measured by the increase in heart weight to body weight ratio, by direct observation of the gross anatomy of the heart, and from echocardiography including increases in left ventricle end systolic diameter and posterior wall thickness 4 or 8 wk after AAC surgery (Fig. 1) . Cu supplementation (20 mg Cu/kg) during the last 4 wk signifi cantly reversed cardiac hypertrophy (Fig. 1) . AAC caused cardiac contractile dysfunction in mice fed 6 mg Cu/kg diet for 4 wk as measured by the percentage of fractional shortening (Fig. 1, %FS ) and ejection fraction (Fig. 1, EF ) using echocardiography. These mice underwent the transition to heart failure at 8 wk after AAC as indicated by further decreases in %FS and EF and a signifi cant increase in the lung weight to body weight ratio. Cu supplementation completely The LV dimensions at end systole (fi rst vertical line) and at end diastole (second vertical line) were increased at the end of 4 wk after AAC, and further dilation occurred 8 wk after AAC, indicating heart failure. (C) Heart weight to body weight ratio (HW/BW, mg/g); lung weight to body weight (LW/BW, mg/g); the quantitative analysis of the recordings from echocardiograph, including the percentage of fractional shortening (%FS); ejection fraction (EF); left ventricle end-systolic diameter (LVESD); and posterior wall thickness (PWT). *, Signifi cantly different from sham-operated controls (P < 0.05, n = 6-12). # , Signifi cantly different from AAC-treated mice fed 6 ppm Cu diet for 4 wk (P < 0.05, n = 6-12).
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reversed the contractile dysfunction and prevented the transition to heart failure ( Fig. 1) .
Histological sections showed cellular hypertrophy along with degenerative morphological changes including necrosis and fi brosis in mice subjected to AAC and fed 6 mg Cu/kg diet for 4 wk, and more severe pathological changes were observed in mice fed the same diet for 8 wk (Fig. 2) . Electron microscopic examination revealed mitochondrial abnormalities including swelling, structural disruption, membrane rupture, and the appearance of amorphous matrix densities in mice fed 6 mg Cu/kg diet for 8 wk (Fig. 2) . In mice fed 20 mg Cu/kg diet during the last 4 wk after AAC surgery, cardiac pathological changes including necrosis, fi brosis, and ultrastructural abnormalities were all eliminated (Fig. 2) . These results thus demonstrate that dietary Cu supplementation reverses preestablished hypertrophic cardiomyopathy induced by chronic pressure overload even in the continued presence of the pathological stimulus.
Cu supplementation restores VEGF levels and promotes angiogenesis in pressure overload hearts The capillary density in the myocardium subjected to AAC for 4 or 8 wk was signifi cantly decreased in mice fed 6 mg Cu/kg diet. However, cardiac VEGF levels were signifi cantly increased 4 wk after AAC, but signifi cantly decreased 8 wk after AAC in mice fed 6 mg Cu/kg. Dietary Cu supplementation during the last 4 wk after AAC restored VEGF levels and increased the capillary density in the heart in spite of the continued presence of pressure overload (Fig. 3) .
Cu concentrations decrease in hearts subjected to pressure overload The total levels of Cu in the hearts of mice subjected to AAC and fed 6 mg Cu/kg diet for 4 wk signifi cantly decreased. Dietary Cu supplementation for 4 wk, started at either the same time with AAC surgery or 4 wk after feeding 6 mg Cu/kg diet, eff ectively prevented or reversed Cu depletion in the heart (Fig. 3) . Cu supplementation did not change cardiac Cu levels in the sham controls (Fig. 3) . To determine the functional signifi cance of Cu depletion in the heart, the activity of a most sensitive Cu-dependent enzyme complex, cytochrome c oxidase (CCO) was measured. As shown in Fig. 3 , CCO activity was signifi cantly depressed 4 wk after AAC and f urther decreased 8 wk (although not signifi cantly diff erent from 4 wk) after AAC surgery. CCO activity was completely restored 4 wk after Cu supplementation. swelling (arrows), structural disruption (asterisks), and membrane rupture (arrowhead) in mitochondria. All of these changes were much more severe at 8 wk but were eliminated by dietary Cu supplementation during the last 4 wk (6/20 ppm) after AAC surgery. Insert in the EM image at 8 wk shows amorphous matrix densities (AMD), a specifi c severe damage to mitochondria. Bars: 50 μm (H/E, SR, and WGA panels); 1.5 μm (EM panels).
Anti-VEGF antibody blunts Cu supplementation-induced regression of hypertrophic cardiomyopathy
We investigated whether or not restoration of myocardial VEGF levels and the associated angiogenesis might be involved in dietary Cu supplementation-induced regression of cardiac hypertrophy and dysfunction by using anti-VEGF antibody. At the time when mice with established cardiac hypertrophy and dysfunction were switched from 6 mg Cu/kg diet to 20 mg Cu/kg diet, they were injected intravenously with anti-VEGF antibody every 3 d for 27 d. This treatment completely blunted Cu supplementation-induced regression of hypertrophic cardiomyopathy. The treatment with anti-VEGF antibody aff ected neither cardiac morphology nor contractile function of the sham controls (Fig. 4) . This result thus suggests that dietary Cu supplementation-induced reversal of heart hypertrophy and dysfunction is mediated at least in part by restoration of myocardial VEGF expression and the associated angiogenesis.
Cu requirement for HIF-1 activation of VEGF expression
Because HIF-1α is a critical transcription factor for VEGF expression, we examined the eff ect of the Cu chelator, tetraethylenepentamine pentahydrochloride (TEPA), on HIF-1α transcription activation in cultured human cardiomyocytes. HIF-1α activation was induced by insulin-like growth factor (IGF)-1, a well-known growth factor stimulating VEGF production by activating HIF-1α, in comparison with the stimulatory eff ect of Cu. Both IGF-1 and Cu activated HIF-1α and stimulated VEGF expression. Importantly, TEPA blocked both the stimulatory eff ect of IGF-1 and that of Cu (Fig. 5) , (E) AAC-induced depression of cardiac CCO activity (CCO/CS ratio) 4 or 8 wk after AAC and the effect of Cu supplementation. *, Signifi cantly different from sham-operated controls (P < 0.05, n = 6). # , Signifi cantly different from AAC-treated mice fed 6 ppm Cu diet for 4 wk (P < 0.05, n = 6).
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suggesting a requirement for Cu in HIF-1α activation of VEGF expression. To further test the requirement of Cu for VEGF expression, varying concentrations of CuSO 4 were added into the cultures containing TEPA, and Cu dose dependently relieved TEPA-mediated suppression of VEGF expression (Fig. 6) , demonstrating that the inhibitory eff ect of TEPA acted through Cu chelation. Furthermore, we determined the requirement of HIF-1α for IGF-1-or Custimulated VEGF expression. We used a siRNA targeting HIF-1α and found that in the absence of HIF-1α, neither Cu nor IGF-1 stimulated VEGF expression in cultured human cardiomyocytes (Fig. 7) .
CCS is involved in the interaction between Cu and HIF-1
The Cu chaparone CCS is involved in the synthesis of active Cu,Zn-SOD (SOD1) by inserting Cu to the apoprotein. We next examined whether or not Cu activation of HIF-1α is also mediated by CCS. We used an anti-CCS antibody to Mice were fed 6 mg Cu/kg diet (6 ppm) for 4 wk after AAC surgery and then were changed to 20 mg Cu/kg diet for the last 4 wk in the presence of anti-VEGF antibody administration once every 3 d. All of the parameters and labels are the same as presented in Fig. 1 and 2 . *, Signifi cantly different from sham-operated controls (P < 0.05, n = 6). C/S, cross section; H/E, hematoxylin and eosin; SR, Sirius red; WGA, wheat germ agglutinin. Bars, 50 μm.
perform an immunoprecipitation assay and found that CCS coimmunoprecipitated with HIF-1α (Fig. 8) . To explore the role of CCS in HIF-1α activation and VEGF expression, we used a siRNA targeting CCS to delete CCS in cultured human cardiomyocytes. In the absence of CCS, neither Cu nor IGF-1 activated HIF-1α or stimulated VEGF expression (Fig. 8) , demonstrating the requirement for CCS in Cumediated activation of HIF-1α transcription activity for VEGF expression. Because CCS also transfers Cu to SOD1, we next used a siRNA targeting SOD1 to eliminate the possibility that the Cu eff ect on VEGF expression is mediated by SOD1. The results, shown in Fig. 9 , demonstrate that in the absence of SOD1, Cu-or IGF-1-stimulated VEGF expression was not suppressed, but in contrary, it was further stimulated.
DISCUSSION
In the present study, we report for the fi rst time that Cu supplementation actually reverses hypertrophic cardiomyopathy induced by chronic pressure overload. The results demonstrate that pressure overload generated by AAC causes a decrease in Cu levels in the heart along with hypertrophic cardiomyopathy and the transition to heart failure in mice fed a diet containing RDA adequate levels of Cu. The most important fi nding is that Cu supplementation to mice with preestablished cardiac hypertrophy and dysfunction in the presence of sustained pressure overload signifi cantly reduced heart hypertrophy and completely restored cardiac contractile function. Cardiac dysfunction is associated with decreased VEGF levels and inhibition of coronary angiogenesis, as demonstrated in previous studies (12, 13) . Cu supplementation increases VEGF levels and promotes angiogenesis in hypertrophic hearts. VEGF plays a crucial role in the regression, as demonstrated by the observation that anti-VEGF antibody blocked Cu supplementation-induced angiogenesis and regression of hypertrophic cardiomyopathy.
Regression of preestablished hypertrophic cardiomyopathy has been shown recently using the phosphodiesterase-5A inhibitor, sildenafi l (14) . Our present results indicate that dietary Cu supplementation should be as eff ective as oral administration of sildenafi l in reversing heart hypertrophy and dysfunction induced by chronic pressure overload. However, the simple and inexpensive dietary Cu supplementation would have obvious advantages over sildenafi l. In particular, the level of the supplemented Cu is within the physiologic Values are mean ± SD (n = 6), and the experiment was repeated two times with consistent results. *, Signifi cantly different from mismatched RNA only treated (B) controls (P < 0.05, n = 6). # , Signifi cantly different from corresponding treated cultures (P < 0.05, n = 6).
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range and well below the maximum tolerable daily intakes (10 mg/day), so that it does not raise safety concerns and should not have the side eff ects (e.g., headache, fl ushing, and vision abnormalities) sometimes associated with sildenafi l administration. The level of Cu supplementation used in the present study would be equivalent to 2.9 mg/day for humans, which can be found if conventional multiple mineral and vitamin supplements are used (2 mg Cu/day from the supplement plus RDA of 0.9 mg Cu/day).
Our fi ndings are of clinical interest in multiple ways. (a) Given the high prevalence of hypertrophic cardiomyopathy, amelioration of these conditions by simply increasing dietary intakes of Cu would be practical and very attractive. (b) Marginal dietary Cu restriction in humans, defi ned as consumption of a diet containing less Cu than the RDA, has been identifi ed from surveys of food consumption (15) (16) (17) . This would adversely aff ect those in the population with cardiac complications. Therefore, it appears reasonable to monitor Cu intakes for these populations. (c) The current RDA for Cu has not considered the special case of individuals with cardiac complications.
The data obtained here demonstrate that functional defi ciency of Cu may occur in these populations and a diff erent RDA for Cu for these populations should be considered. (d) Cu chelation therapy for cancers has recently been in clinical trials (18) , but the potential adverse eff ects of Cu chelation on patients with heart disease need to be evaluated.
An important question is how Cu supplementation causes reversal of hypertrophic cardiomyopathy. We believe that one viable possibility is the eff ect of Cu on the synthesis of VEGF. A recent study has demonstrated that a lack of coordination between cardiac hypertrophy and angiogenesis (caused by suppression of VEGF activity) is associated with the progression of cardiac hypertrophy to heart failure (12). Acute phase of adaptive cardiac growth is associated with enhanced myocardial VEGF expression, coronary angiogenesis, and preservation of cardiac contractile function. Chronic and pathological hypertrophy is associated with depression of VEGF production and reduced angiogenesis (12) . The study has defi ned that the decrease in VEGF levels is associated with the switching from adaptive to pathological hyper trophy under stress conditions (12) . In the present study, we also observed that VEGF production was increased in the early phase, but decreased in the late phase of cardiac hypertrophy induced by sustained pressure overload. However, Cu supplementation restored VEGF production in the late phase of cardiac hypertrophy even in the continued presence of pressure overload. Western blot analysis shows that treatment of the cells with the CCS siRNA for 48 h silenced the CCS expression but mismatched siRNA (MMsiRNA) did not. After treatment with the CCS siRNA for 48 h, the cells were incubated with IGF-1 or Cu for 16 h. HIF-1α transcription activity was assayed using the cell lysate by an ELISA assay and VEGF concentrations in culture media by an ELISA assay and normalized by cell numbers. CCS siRNA signifi cantly suppressed the transcription activity of HIF-1α and VEGF expression. Values are mean ± SD (n = 6), and the experiment was repeated two times with consistent results. *, Signifi cantly different from unstimulated control (P < 0.05, n = 6). # , Signifi cantly different from corresponding mismatched RNA treated cultures (P < 0.05, n = 6). Cu regulation of VEGF expression has been suggested in several studies (19) (20) (21) (22) . One study has shown that, at physiologic concentrations, Cu induces the synthesis of VEGF, which promotes angiogenesis in a healing wound (23) . In Cu-defi cient mouse hearts, generated by dietary Cu restriction, VEGF expression was markedly depressed and Cu repletion of the diet completely restored the expression of VEGF in the heart (22) along with regression of Cu deficiency-induced hypertrophic cardiomyopathy (24) . The data presented here further demonstrate the link between Cu and VEGF production and the associated angiogenesis in the heart. Here, we have specifi cally addressed the question of whether or not VEGF is necessary for the regression of hypertrophic cardiomyopathy. The results clearly show that anti-VEGF antibody-mediated depletion of VEGF prevents Cu supplementation-induced reversal of hypertrophic cardiomyopathy, demonstrating the necessary role of VEGF in the regression.
Is Cu required for VEGF expression in cardiomyocytes? Cu at physiologically relevant levels stimulated VEGF expression, which mimicked the eff ect of IGF-1 in cultured human cardiomyocytes. The Cu chelator TEPA suppressed not only Cu-stimulated, but also IGF-1-induced VEGF production, indicating that Cu is required for IGF-1-activated VEGF expression. Furthermore, the basal level of VEGF expression was also decreased in the TEPA-treated control cultures, and addition of excess Cu into TEPA treated cultures restored VEGF expression. Therefore, these results strongly indicate that Cu is essential for VEGF expression in cardiomyocytes.
How does Cu regulate VEGF expression? The results showed that HIF-1α was critically involved in the Cu regulation of VEGF expression. The in vitro data that siRNA targeting HIF-1α abolished Cu stimulation of VEGF expression demonstrate an essential role of HIF-1α in Cu-dependent VEGF expression in the heart. In the cell, there is virtually no free Cu (25) , so that Cu chaperones direct Cu transport specifi cally to its target molecules. For instance, CCS has been identifi ed as a Cu chaperone for SOD1 (26) . CCS interacts directly with SOD1 for the insertion of ionic Cu into the metalloprotein (25) . This effi cient Cu delivery mechanism avoids ineffi cient and potentially dangerous traffi cking of Cu within the cell. In this context, the interaction between Cu and HIF-1α could also be mediated by a Cu chaperone such as CCS. In fact, we found that CCS coimmunoprecipitated with HIF-1α. This is an important novel observation, as it indicates that CCS may not only transfer Cu ion to SOD1 but to other proteins as well. It also indicates that a direct interaction between CCS and the Cu requiring apoproteins may represent a common mechanism for Cu transfer in the cell. However, it is the Cu requiring apoproteins that determine the functional specifi city. In this context, we have excluded the possible involvement of SOD1 in Cu regulation of VEGF by showing that SOD1 gene silencing did not inhibit IGF-1-or Cu-stimulated VEGF expression. An unresolved issue is how Cu interacts with HIF-1α through CCS, a question that will require more extensive chemical and structural studies.
The result obtained from the use of siRNA targeting CCS demonstrated the importance of CCS in the regulation of Cu-activated HIF-1α transcription activity and VEGF expression. The inhibitory eff ect of CCS gene silencing on IGF-1-induced HIF-1α activation and VEGF expression was as the same as that of Cu chelator, TEPA. Since CCS is a Cuspecifi c chaperone, the CCS gene silencing result not only provides a mechanistic insight into Cu regulation of VEGF expression but also supports the conclusion obtained from the Cu chelator study for the essentiality of Cu in the regulation of VEGF expression. The CCS gene silencing result also excludes a possible confounding eff ect of nonspecifi c metal chelation by TEPA on IGF-1-induced HIF-1α activation and VEGF expression.
This study for the fi rst time presents evidence that Cu is required for HIF-1α activation and VEGF expression in cardiomyocytes. Cu activation of HIF-1α is mediated by CCS, which appears to directly interact with HIF-1α. The results provide a scientifi c rationale for Cu supplementation as a means of causing the regression of hypertrophic cardiomyopathy induced by sustained pressure overload. Should similar eff ects of Cu supplementation be found in controlled studies in human patients, this will point the way to a simple, nontoxic and extraordinarily economical therapy for hypertrophic cardiomyopathy.
MATERIALS AND METHODS
Animal models. Male C57BL/6J mice (10-12 wk old; The Jackson Laboratory) were fed standard AIN-93 diet (27) containing 6 mg Cu/kg, which is the adequate level of Cu for mice according to the RDA established by Food and Nutritional Board of the Institute of Medicine (2) and is equivalent to current RDA for humans (0.9 mg Cu/day). Pressure overload was produced by AAC as described previously (28) (29) (30) . In brief, mice were anesthetized and ventilated with a rodent respirator. Aortic constriction was made through a left thoracotomy by placing a ligature using a 6-0 silk suture securely around the ascending aorta and a 26 1/2-gauge blunted needle and then removing the needle. For the sham operation, the left thoracotomy was made but the aorta was not ligated. The animal survival rate due to the AAC surgery was 80% including postsurgical death. The animal procedure was approved by the Institutional Animal Care and Use Committee, which is certifi ed by the American Association of Accreditation for Laboratory Animal Care.
4 wk after the AAC surgery, some mice were sacrifi ced for analyses. One group of AAC mice was changed to a diet containing 20 mg Cu/kg, and the other group remained on the 6 mg Cu/kg diet. The supplementation level of Cu in the diet is equivalent to 2.9 mg Cu/day in humans, an intake easily reached if conventional multiple mineral and vitamin supplements are used (2 mg Cu/day plus RDA of 0.9 mg Cu/day). The mice were harvested for the analyses at either 4 or 8 wk after AAC. At the time of harvesting, heart weight to body weight ratio and lung weight to body weight ratio were obtained. Although there were premature deaths of some AAC mice fed 6 mg Cu/kg diet for 8 wk, the number of mice for each parameter measured was six or greater.
Anti-VEGF treatment. Anti-mouse VEGF antibody (R&D Systems, Inc.), 20 μg in 200 μl PBS, was given every 3 d by intraperitoneal injection to some mice starting when the mice were switched to the 20 mg Cu/kg diet after feeding 6 mg Cu/kg diet for 4 wk in both AAC surgery and sham controls. The treatment lasted for 27 d.
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Echocardiography. Two-dimensional images of the left ventricle were obtained from the apical four-and two-chamber views with a phased-array echocardiography (SONOS 1500 or 2500; Hewlett-Packard, Inc.) and a 2.5-MHz transducer in anesthetized mice. The images were recorded on 1/2-inch videotape for subsequent review and analysis. With the use of a commercially available microcomputer system (GTI; Freeland), the echocardiograms were analyzed qualitatively and quantitatively for the development of regional LV wall motion abnormalities. Quantitative analysis was performed by use of a centerline method that constructs 100 equidistant chords perpendicular to a line centered between digitized LV end-diastolic and end-systolic endocardial borders.
Cu concentrations in the heart. Total Cu concentrations were determined in the heart using inductively coupled argon plasma emission spectroscopy (model 35608; Thermo ARL-VG Elemental) after lyophilization and digestion of the tissues with nitric acid and hydrogen peroxide (31) . To confi rm the dietary Cu concentrations, a dry-ashing procedure was used. This procedure included dissolution of the residue in aqua regia and measurement by atomic absorption spectrophotometry (model 503; PerkinElmer).
Assessment of morphology changes. Hearts were excised, washed with saline solution, and placed in 10% formalin. Hearts were cut transversely close to the apex to visualize the left and right ventricles. Several sections of heart (4-5-μm thick) were prepared and stained with hematoxylin and eosin for histopathology or sirius red for collagen deposition and visualized by light microscope. Capillaries were visualized in frozen left ventricle sections stained with antibodies to endothelial cell adhesion molecule-1 (PECAM-1 or CD31) (Santa Cruz Biotechnology Inc.). The capillary density was assessed by a computer-assisted image analyzer (SigmaScan Pro5.0; SPSS, Inc.). Three fi elds at 200× magnifi cation per heart were analyzed, and six mice in each group were examined for the calculation. For examination by electron microscopy, a tissue sample preparation procedure described previously (32) was used.
Cell culture studies. Human cardiac myocytes (HCMs) along with the culture medium were purchased from ScienCell Research Laboratories. The culture medium was composed of basal medium, 5% FBS, 1% cardiac myocyte growth supplement, and 1% penicillin/streptomycin solution (ScienCell). Cells were maintained at 37°C in a 95% humidifi ed air and 5% CO 2 . Before each experiment, monolayer HCMs were allowed to grow to 90% confl uence, and switched to low-serum medium (basal medium supplemented with 1% FBS) for 24 h, then exposed to 100 ng/ml IGF-1 (Sigma-Aldrich), 25 μM CuSO 4 (Sigma-Aldrich), or 25 μM TEPA (Sigma-Aldrich) in the low-serum medium, alone or in combination. The culture media were collected for VEGF measurement, and cells were harvested and subjected to HIF-1 activity assay at 16 h after the treatment.
Gene silencing. siRNAs targeting human HIF-1α, CCS, and SOD1 and negative mismatched control siRNA were designed and synthesized by Ambion. The siRNA sequences for HIF-1α were sense, G G C C U C U G U G-A U G A G G C U U tt and antisense, A A G C C U C A U C A C A G A G G C C tt. The siRNA sequences for CCS, sense, G G A C C A G A U G G U C U U G G U A tt, and antisense, U A C C A A G A C C A U C U G G U C C tt. A validated SOD1 siRNA was obtained from the same company (siRNA ID no.: 119429). After the monolayer HCM cultures reached 50% confl uence, the cells were transfected with 100 nM annealed siRNAs targeting specifi c genes or negative mismatched siRNA using a Silencer siRNA transfection kit (Ambion) according to the manufacturer's instruction. At 48 h after the transfection, the culture media were changed to the low-serum medium for 24 hr, and then exposed to 100 ng/ml IGF-1 or 25 μM CuSO 4 alone or in combination. Some cultures were exposed to 150 μM CoCl 2 (Sigma-Aldrich) to increase HIF-1α levels. The culture media were collected for VEGF measurement, and cells were harvested and subjected to HIF-1 analysis at 16 h after the last treatment.
HIF-1 activity assay. The nuclear extracts of cultured cells were obtained by using a nuclear extract kit (Active Motif) according to the manufacturer's instruction. HIF-1 activity was quantifi ed in 5-10 μg of nuclear extracts by specifi c binding of HIF-1 to an oligonucleotide containing the HRE from the EPO gene (5′-TACGTGCT-3′) using a TransAM HIF-1 transcription factor assay kit (Active Motif) following the manufacturer's instruction. Each sample was measured in duplicate, and the measured activity was normalized to total protein content measured by a Bio-Rad Laboratories protein assay kit.
Quantitative analysis of VEGF. VEGF in culture media was measured using a Quantikine Human VEGF Immunoassay (R&D Systems) according to the manufacturer's instruction. Each sample was measured in duplicate, and the VEGF concentrations were normalized by the number of cells in each culture sample.
Enzymatic assay for CCO. Mitochondria were isolated from fresh heart samples using a mitochondrial isolation kit (Pierce Chemical Co.) following the instruction provided. CCO was assayed as described previously (33) . In brief, CCO was measured by adding ferrocytochrome c in an isosmotic medium (10 mM KH 2 PO 4 , pH 6.5, 1 mg/ml bovine albumin, 0.3 M sucrose). The activity was calculated from the rate of decrease in absorbance of ferrocytochrome c at 550 nM (ε = 19.1 mM −1 cm −1 ) and normalized by mitochondrial protein content. Because accurate estimations of CCO activity could be compromised by variations in mitochondrial yield and integrity, the CCO activity in the present study was normalized using an invariant marker of mitochondrial enzyme activity, citrate synthase. Citrate synthase was assayed by following the reduction of 5,5′-dithio-bis(2-nitrobenzoic acid) (2 mM) in the presence of acetyl-CoA (0.1 mM) and oxalacetic acid (12 mM) in a medium containing 10 mM KH 2 PO 4 , pH 7.8, 2 mM EDTA, 1 mg/ml BSA, and 0.1% Triton X-100. The change in absorbance at 412 nm was monitored for 30 min (refl ecting the formation of thionitrobenzoate). The citrate synthase activity was calculated from the change in absorbance using ε = 13.6 mM −1 cm −1 , and normalized by mitochondrial protein content.
Immunoprecipitation analysis of CCS and HIF-1 . HCM cell lysates were prepared in ice-cold IP buff er containing 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100, 10% glycerol and protease inhibitor cocktail (Sigma-Aldrich). Crude cell lysates containing 300 μg protein were precleared by incubating with protein G-Sepharose 4FF (GE Healthcare) and mixed with 4 μg of rabbit anti-CCS antibody (FL-274; Santa Cruz Biotechnology, Inc.) and incubated at 4°C overnight under rotation. 30 microliters of preequilibrated protein G-Sepharose 4FF were then added and incubated for 1 h at 4°C under rotation. After centrifugation at 1,000 g for 2 min, supernatants were removed, and the beads were washed three times with the IP buff er. The resulting immunocomplex-containing beads were treated with SDS sample buff er and subjected to Western blot analysis.
Western blot analysis of proteins. The sample preparation from frozen mouse hearts and cultured cells, gel electrophoresis, and transfer to blotting membranes were described previously (34, 35) . Nonspecifi c binding was blocked by using a blocking buff er (5% nonfat dry milk, Tris-buff ered saline: 20 mM Tris-HCl, pH 7.5, 500 mM NaCl, 0.5% Tween 20) for 2 h at room temperature, and then the blotting membranes were incubated overnight at 4°C with the following primary antibodies diluted in blocking buff er: rabbit anti-human SOD1 polyclonal antibody (1:1,000 Santa Cruz Biotechnology, Inc.), mouse anti-human HIF-1α monoclonal antibody (1 μg/ml; Sigma-Aldrich), goat anti-mouse VEGF polyclonal antibody (2 μg/ml; R&D Systems), rabbit anti-human CCS (1:2,000; Santa Cruz Biotechnology, Inc.), and mouse anti-GAPDH monoclonal antibody (1:5,000; StressGen Biotechnologies). The membranes were washed in Tris-buff ered saline, 1% Tween 20 (TBST) and incubated for 2 h at room temperature with HRP-conjugated rabbit anti-goat IgG and goat antimouse or rabbit IgG antibodies (1:20,000; Southern Biotechnology Associates, Inc.) diluted in TBST. The blots were processed and visualized by chemiluminescence (GE Healthcare).
Statistical analysis. Data were expressed as mean ± SD values and analyzed by ANOVA followed by a Duncan's multiple-range test for further determination of the signifi cance of diff erences. Diff erences among groups were considered signifi cant when P < 0.05.
